Cantharidin

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

Retrieved on: 
Monday, February 5, 2024
Dormer, Sale, Therapy, Molluscum contagiosum, Skin, Cantharidin, Safety, Dermatology, FDA, Marketing, Pharmaceutical industry

WEST CHESTER, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has filed a lawsuit in the Eastern District of Pennsylvania against Dormer Laboratories Inc., a Canada corporation (“Dormer Labs”) requesting, among other relief, that the court enjoin Dormer Labs from marketing, selling, and distributing drugs containing cantharidin in the United States, as well as compensatory, statutory and punitive damages for Dormer Labs’ violations of the federal Lanham Act and Pennsylvania law. The lawsuit arises out of Dormer Labs’ false and misleading advertising and promotion of unapproved cantharidin-containing drugs to health care providers and other customers in the United States.

Key Points: 
  • The lawsuit arises out of Dormer Labs’ false and misleading advertising and promotion of unapproved cantharidin-containing drugs to health care providers and other customers in the United States.
  • YCANTH was the first FDA-approved treatment for molluscum contagiosum.
  • YCANTH is also the only FDA-approved cantharidin-containing drug, meaning that it is the only cantharidin-containing drug that FDA has determined to be safe and effective.
  • This lawsuit is part of Verrica’s commitment to patient safety by stopping the false and misleading advertising and sale of unapproved cantharidin-containing drugs within the United States.

Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET

Retrieved on: 
Monday, July 24, 2023
GMP, Term sheet, Cantharidin, Therapy, SOFR, Pain, Dermatology, Erythema, Patient, Molluscum contagiosum, Itch, SPA, Webcast, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, City of Fresno discolored water investigation, Skin, Pharmaceutical industry

The facility is a five-year term loan that matures in July 2028.

Key Points: 
  • The facility is a five-year term loan that matures in July 2028.
  • Later this morning, the Company will host a conference call and webcast at 8:30 a.m.
  • The conference call dial-in numbers are (877) 407-4018 (domestic) or (201) 689-8471 (international) and the access code is 13740240.
  • The discontinuation rate due to an adverse reaction was 2.3% among subjects treated with YCANTH™ and 0.5% among subjects treated with vehicle.

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Retrieved on: 
Friday, July 21, 2023
GMP, Skin discoloration, Swimming, Cantharidin, Therapy, Food and Drug Administration, Pain, School, Dermatology, Erythema, Patient, Molluscum contagiosum, Physician, Itch, FDA, Safety, Food, Caregiver, Skin, Vaccine, Pharmaceutical industry

WEST CHESTER, Pa., July 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced U.S. Food and Drug Administration (FDA) approval of YCANTH™ (cantharidin) topical solution for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients 2 years of age and older.

Key Points: 
  • ET –
    WEST CHESTER, Pa., July 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced U.S. Food and Drug Administration (FDA) approval of YCANTH™ (cantharidin) topical solution for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients 2 years of age and older.
  • Molluscum, which primarily affects children, is highly contagious and is commonly transmitted in households, schools, swimming pools and other extra-curricular settings.
  • Since molluscum spreads through skin-to-skin contact and the sharing of contaminated objects with its viral lesions, a topical treatment with precise administration is essential towards preventing further transmission.
  • The webcast can be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com .

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
Skin, New Drug Application, Dermatology, Therapy, CMC, Insurance, Cantharidin, Molluscum contagiosum, Table, Bank statement, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Part, GAAP, Patient, Pharmacokinetics, Food, Carcinoma, Collaboration, FDA, Research, Safety, WEST, PDUFA, Wart, Pharmaceutical industry, Vaccine, Cryptocurrency, Torii

WEST CHESTER, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Verrica expects to initiate Part 2 of its ongoing Phase 2 study in basal cell carcinoma in the second quarter of 2023.
  • Verrica reported a net loss of $5.9 million for the fourth quarter of 2022, compared to a $9.5 million loss for the same period in 2021.
  • Research and development expenses were $3.0 million in the fourth quarter of 2022, compared to $3.4 million for the same period in 2021.
  • General and administrative expenses were $3.2 million in the fourth quarter of 2022, compared to $5.1 million for the same period in 2021.

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

Retrieved on: 
Monday, February 27, 2023
Safety, PDUFA, Cantharidin, Prescription Drug User Fee Act, WEST, Skin, Molluscum contagiosum, GMP, FDA, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, NDA, Therapy, Food, Pharmaceutical industry

WEST CHESTER, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the Company’s resubmitted New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (“molluscum”) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 23, 2023.

Key Points: 
  • “We are pleased that the FDA has accepted for filing our NDA resubmission for VP-102,” said Ted White, Verrica’s President and Chief Executive Officer.
  • “With no FDA-approved treatments for molluscum, the filing acceptance of our NDA brings us one step closer towards providing a safe and effective therapeutic treatment option for the millions of patients in the United States with molluscum.
  • VP-102 has been designed for reliable and targeted administration of cantharidin through a unique, topical, GMP-controlled formulation through a single-use applicator.
  • Based upon the strong safety and efficacy results from our two Phase 3 clinical trials, we believe that VP-102 has the potential to offer an important new treatment option for molluscum.”

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Exercise, Skin, Company, CMC, CRL, Genetically modified bacteria, Dermatology, Collaboration, Squamous cell carcinoma, Fomite, U.S. Securities and Exchange Commission, Pharmacokinetics, Inflammation, Research, GAAP, Patient, Private Securities Litigation Reform Act, Wart, Itch, Mission statement, Achievement, United, Clinical trial, Social stigma, Physician, Sibling, Table, Molluscum contagiosum, NDA, FDA, Caregiver, Income, GLOBE, Cantharidin, Technology transfer, Safety, Disease, Pain, Therapy, Pharmaceutical industry, Reinsurance, Air cargo, Torii, Piramal, Chemistry

WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2022.

Key Points: 
  • WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2022.
  • Research and development expenses were $2.9million in the third quarter of 2022, compared to $3.8 million for the same period in 2021.
  • General and administrative expenses were $3.9million in the third quarter of 2022, compared to $8.0 million for the same period in 2021.
  • As of September 30, 2022, Verrica had aggregate cash, cash equivalents, marketable securities and restricted cash of $39.5million.

Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Dermatology, Hand, NDA, Table, Inflammation, GLOBE, Food, Private Securities Litigation Reform Act, CRL, Molluscum contagiosum, Disease, Achievement, Pain, Torii, Itch, Endpoint security, Laboratory of design, manufacturing and control, CMO, Company, Mission statement, Wart, Genetically modified bacteria, Therapy, Skin, Collaboration, Technology transfer, GAAP, Research, New Drug Application, Cantharidin, Social stigma, CMC, Fomite, Sibling, Pharmaceutical industry, Fine chemical, Security (finance), Reinsurance, Bank, Online gambling, Piramal, Chemistry

WEST CHESTER, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2022.

Key Points: 
  • WEST CHESTER, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2022.
  • The gross proceeds from the offering to Verrica were approximately $28.5 million, before deducting underwriting discounts and commissions and offering expenses.
  • Research and development expenses were $4.2million in the second quarter of 2022, compared to $3.4 million for the same period in 2021.
  • General and administrative expenses were $5.2million in the second quarter of 2022, compared to $7.3 million for the same period in 2021.

VRCA FRIDAY DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action – VRCA

Retrieved on: 
Thursday, August 4, 2022
Titan, Lists of schools in England, I-Space (Chinese company), Food, THE, Facebook, Advertising, Class, LinkedIn, Molluscum contagiosum, Cantharidin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TO, WHY, GLOBE, New Drug Application, Court, Twitter, NASDAQ, Insurance, Tobacco

WHAT TO DO NEXT: To join the Verrica class action, go to https://rosenlegal.com/submit-form/?case_id=6828 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Verrica class action, go to https://rosenlegal.com/submit-form/?case_id=6828 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Common Warts Drug Pipeline Report 2022 Featuring Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, & NIELSEN BioSciences - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 3, 2022
Health, Pharmaceutical, Wart, Molluscum contagiosum, WHIM syndrome, Route of administration, Patient, WHIM, CXCR4, GMP, Cantharidin, Administration, Therapy, Route, Pharmaceutical industry, Vaccine

The "Common Warts - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Common Warts - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This ''Common Warts - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Warts pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Common Warts.
  • The companies which have their Common Warts drug candidates in the most advanced stage, i.e phase III include X4 Pharmaceuticals
    Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan

Retrieved on: 
Monday, August 1, 2022
License, GLOBE, End-user license agreement, Cantharidin, Skin, U.S. Securities and Exchange Commission, Dermatology, Molluscum contagiosum, Partnership, Private Securities Litigation Reform Act, Social stigma, Sibling, Achievement, Inflammation, Wart, Disease, FDA, Company, Fomite, Pain, Therapy, Genetically modified bacteria, Prevalence, Itch, Pharmaceutical industry, Torii

WEST CHESTER, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Torii Pharmaceutical Co., Ltd. (“Torii”) dosed the first patient in its Phase 3 trial of VP-102 (referred to as TO-208 in Japan) for molluscum contagiosum in Japan, triggering an $8 million milestone payment from Torii to Verrica.

Key Points: 
  • We are pleased to see Torii dose the first patient in its Phase 3 trial of VP-102 for the treatment of molluscum contagiosum in Japan, said Ted White, Verricas President and Chief Executive Officer.
  • In March 2021 Torii exercised its option to acquire the exclusive license to develop and commercialize Verricas product candidates for the treatment of molluscum contagiosum and common warts in Japan.
  • Torii is responsible for all development activities and costs in support of obtaining regulatory approval in Japan.
  • In addition, Verrica has successfully completed a Phase 2 study ofVP-102for the treatment of common warts and a Phase 2 study ofVP-102for the treatment of external genital warts.